Table 1.
Demographic and clinical characteristics of (a) patients group and controls group and (b) follow-up group and non follow-up group.
Table 2.
Anatomical structures showing significant GM abnormalities (a) decreased GM volume at baseline in patients with schizophrenia (n = 20) compared to healthy controls (n = 24); (b) increased GM volume from baseline to follow-up (8 weeks of treatment) in patients with schizophrenia (n = 9).
Fig 1.
Regions of decreased grey matter volume at baseline in antipsychotic-naïve patients with schizophrenia compared to healthy controls. P<0.001, uncorrected, threshold = 50.
Fig 2.
Regions of increased grey matter volume from baseline to follow-up in patients with schizophrenia.
Table 3.
Differences in PANSS scores from baseline to follow-up.